Introduction
Miconazole is an imidazole drug, inhibitory in vitro against almost all pathogenic fungi (Van Cutsem and Theinpont, 1972) . It is effective against experimental fungus disease in animals (Levine et al., 1975) . It is effective used topically for cutaneous, oral and vaginal infections in man (Anonymous, 1974; Sawyer et al., 1975; Brincker, 1977) . The drug has been under study or in general clinical use in several countries as parenteral therapy against systemic fungal infections in man (Stevens, 1977) . This year (1978) (Stevens, 1977) . Chronic pulmonary disease is the most responsive and meningitis the least. Every patient with paracoccidioidomycosis studied responded to therapy . Miconazole therapy seems to be the treatment of choice for petriellidiosis, since Petriellidium boydii is resistant to other available drugs (Lutwick et al., 1979) . Other workers have demonstrated the effectiveness of this compound against oesophageal candidiasis (Verhaegen, 1977) and chronic mucocutaneous candidiasis (Fischer et al., 1977) , as well as the diseases already mentioned. Side effects are principally hyponatraemia, anaemia, nausea and pruritus, and are reversible. A potential problem with this agent is relapse after successful therapy (Stevens, 1977) . It was suggested that this related to the relative brevity of the courses of treatment for which there are several reasons. It was decided that admission to hospital was necessary because of the rapid disappearance from the blood of the drug and the resultant desire to give multiple doses per day. Recent analysis of experience with one manifestation of coccidioidal disease has now clearly indicated that in responders, relapse is associated with short courses of treatment (S. C. Deresinki and D. A. Stevens, in press ).
These results were encouraging and further molecular modifications of the side chains on the imidazole ring were made by the chemists at Janssen Pharmaceutica, Beerse, Belgium. Several compounds were screened and tested (Levine, 1976) (Levine et al., 1975; Galgiani and Stevens, 1976 . This is significant in relation to the clinical results with Paracoccidioides sp. It should be noted that those methods of in vitro susceptibility testing whose results vary with inoculum size will show variability of inoculum size with ketoconazole (Brass and Stevens, 1978) , as with miconazole (Galgiani and Stevens, 1976) . (57) 160 (135) exceed considerably the MICs for the pathogens tested. The intermediate dose tested gave detectable levels for 5 hr, but as shown in Table 3 higher doses gave detectable blood levels for at least 8 hr. Ketoconazole in experimental models These pharmacological observations are consistent with some early experiments in animal models. The results of studies with ketoconazole therapy of experimental coccidioidomycosis are summarized in (Levine et al., 1975) . No development of resistance by the pathogen after in vivo therapy could be shown. However, with higher doses and more prolonged therapy, eradication of (unpublished) have studied the pharmacokinetics following oral administration of 200 mg to man. Peak blood levels of 6 mg/l were reached at 2 hr, and levels exceeded 1 mg/l for > 4 hr. Their later studies indicated that plasma levels after higher doses were relatively higher than after lower doses (e.g. peak levels after 100 mg were 25% of those after 200 mg), consistent with the authors' data for mice as presented above. It also appears that less drug is needed for man on a per-weight basis, to produce blood levels comparable to those in mice.
The authors performed protein-binding studies with equilibrium dialysis methods (Stevens, Levine and Deresinski, 1976) 4 remain on prolonged maintenance therapy, as previously suggested Case 4 (43 years) had a 4-month history of neck nodules, with spontaneous purulent drainage, and weight loss. Chest X-ray showed infiltrates and fibrosis. Cultures of sputum and drainage yielded P. brasiliensis. The neck lesions started to heal by the 10th day of therapy and the draining sinus had cleared by the 18th day. By the second month of therapy only a scar remained in this area, the patient regained some weight. He has now returned to work, sputum production has ceased, and the X-ray has begun to clear.
Case 5 (17 years) had relapsed 14 months after combined amphotericin B + sulphonamide + miconazole therapy, with disseminated cutaneous disease. The skin lesions showed improvement after one week of treatment. Therapy was stopped after 1-5 months of treatment, and the lesions had cleared.
Relapse, however, occurred 15 days later.
The sixth patient is non-evaluable; this emaciated 57-year-old with a 13-month history of weight loss, fever, dyspnoea and sputum production, had bilateral alveolar infiltrates on X-ray. He died, after only 6 days' therapy, of undiagnosed causes, with hypotension and congestive heart failure.
Two patients with cutaneous sporotrichosis were treated. A 24-year-old man had 7 skin lesions, and concurrent, diagnosed, cutaneous tuberculosis. The lesions cleared completely on 3 months' therapy concurrent with antituberculous therapy, and Sporothrix schenkii could not then be grown from the skin. He is in remission 3 months after discontinuation of therapy. A 22-year-old woman was treated for one week, and showed no change.
Two patients with cadidiasis were treated. A 29-year-old man with chronic mucocutaneous candidiasis of 8 years' duration had previously shown temporary responses to nystatin, tolnaftate, and miconazole. His mouth, perineum and nails were involved, and Candida albicans was cultured. The lesions cleared after the third day of therapy, which was discontinued after 8 days. Cultures were then negative. He remains in remission 6 months later. A 13-year-old girl with chronic oral candidiasis cleared her disease with daily therapy, which has been gradually reduced to a maintenance dose of 200 mg once a week, and she remains in remission 6 months after therapy was started.
A 21-year-old man with a 3-month history of coccidioidomycosis of the tibia, with overlying sinus tracts and cutaneous involvement was treated for 3 months. In this time the lytic lesion in the tibia cleared, as did the skin, and cultures became negative for Coccidioides immitis.
A 32-year-old man with severe pharyngeal and miliary pulmonary histoplasmosis, with positive marrow cultures responded promptly and was discharged from hospital after 3 weeks' therapy, after his pharyngeal cultures had reverted to negative. After 2 months' therapy all clinical evidence of disease had cleared, and the chest X-ray was clearing. He remains in remission 6 months later.
Two men, aged 16 and 18 years, both had concurrent pityriasis versicolor (Malassezia furfur) and tinea (Epidermophyton floccosum) of the legs and feet (and, in one case, also the trunk). Three weeks' treatment cleared their lesions, and skin scrapings were negative on culture. They remain in remission 3 and 4 months after termination of therapy.
An 18-year-old man with pityriasis versicolor was cured on 2 weeks' therapy, and remains in remission 3 months later.
A 42-year-old diabetic man with chromoblastomycosis of 6 years' duration was treated for 3 weeks, without change.
Two patients with mycetomas failed to respond. One 65-year-old man had a mixed Monosporium apiospermum/Aspergillus sp. infection of the ankle and foot of 18 years' duration. A 64-year-old man had a Nocardia brasiliensis infection of the femur and lower leg of 10 years' duration. Therapy of 43 and 56 days respectively produced no change.
Toxicology of ketoconazole in man
No subjective symptoms were noted by any of the patients on therapy. The haematocrit, haemoglobin, leukocyte count and differential were performed before, during, and after therapy in 12 patients; serum glucose and creatinine determinations and urine analysis in 11; platelet count, serum calcium, cholesterol, protein, SGOT, bilirubin, sodium, potassium, chloride in 10; serum phosphate and prothrombin time in 9; partial thromboplastin time and slit lamp eye examinations in 6; and serum bicarbonate in 4 patients. None of these determinations showed any abnormalities induced by the drug, with the possible exception of one patient who had a transient rise in SGOT which returned to normal, even though he remained on therapy at the same dose.
Conclusion
Ketoconazole appears to be a promising antifungal agent with desirable pharmacological properties and limited toxicity. Further extensive clinical studies are warranted.
